TerSera Therapeutics Acquires Xermelo and Continued NET Patient Nursing Support Services

TerSera Therapeutics recently acquired Xermelo (telotristat ethyl) from Lexicon Pharmaceuticals. Xermelo is the first and only FDA-approved prescription medicine, used along with somatostatin analog (SSA), for carcinoid syndrome diarrhea in adults who are inadequately controlled by SSA therapy.  Lexicon’s Clinical Nurse Educator team has transitioned to TerSera Therapeutics.  As such, there will be no disruption in Xermelo nursing support for neuroendocrine tumor patients.  If you would like to speak with a Clinical Nurse Educator, visit www.enrollxermelo.com to enroll and a nurse will contact you within 48 hours.

Print Friendly, PDF & Email